Lauri Lehtimäki

Medicine & Life Sciences

1. Asthma 100%
2. Finland 33%
3. Adrenal Cortex Hormones 20%
4. Nitric Oxide 19%
5. Workplace 16%
6. Registries 16%
7. Preschool Children 15%
8. Dyspnea 13%
9. Biological Therapy 12%
10. SARS Virus 11%
11. Bronchodilator Agents 11%
12. Bronchoconstriction 11%
13. Population 11%
14. Scandinavian and Nordic Countries 10%
15. Respiratory Sounds 10%
16. Nasal Polyps 9%
17. Dust 9%
18. Biological Products 9%
19. Interleukin-5 9%
20. Multiple Chemical Sensitivity 9%
21. Eosinophils 9%
22. Lung 9%
23. Exercise 9%
24. anti-IgE antibodies 8%
25. Chronic Obstructive Pulmonary Disease 8%
26. Respiratory Insufficiency 8%
27. Child 8%
28. Inhalation Spacers 8%
29. Nose 8%
30. Sweden 8%
31. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 8%
32. Respiratory System 7%
33. Cross-Sectional Studies 7%
34. Occupational Groups 7%
35. Humidity 7%
36. Complement Factor D 7%
37. Pollen 7%
38. Peanut Hypersensitivity 7%
39. Guidelines 7%
40. Steroids 6%
41. Denmark 6%
42. Exhalation 6%
43. Multimorbidity 6%
44. Masks 6%
45. Life Style 6%
46. Arachis 6%
47. reslizumab 5%
48. Treatment Adherence and Compliance 5%
49. Noninvasive Ventilation 5%
50. Fees and Charges 5%